Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.51 |
| ▸ | ACACA | Q13085 | 11/20 | 0.51 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | EDNRB | P24530 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350676 | 0.87 | ACACB (0.52) | ACACBACACAPGRPTGS2EDNRB | |
| SCHEMBL811925 | 0.85 | PTGS2 (0.47) | ACACBACACAPGRPTGS2ALOX5 | |
| SCHEMBL2352301 | 0.85 | ACACB (0.52) | ACACBACACAPGRPTGS2EDNRB | |
| SCHEMBL12128937 | 0.83 | ACACB (0.50) | ACACBACACAPGRALOX5CA12 | |
| SCHEMBL812007 | 0.83 | PGR (0.40) | ACACBACACAPGRPTGS2EDNRA | |
| SCHEMBL2349821 | 0.82 | ACACB (0.49) | ACACBACACA | |
| SCHEMBL2356692 | 0.82 | ACACB (0.49) | ACACBACACA | |
| SCHEMBL28606507 | 0.81 | PTGS2 (0.49) | PGRPTGS2EDNRAPTGS1 | |
| SCHEMBL2361957 | 0.81 | ACACB (0.48) | ACACBACACAPGR | |
| SCHEMBL2350565 | 0.81 | ACACB (0.47) | ACACBACACAPGRPTGS2EDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962599-B1 | INSECTICIDE COMPOUNDS WITH IMPROVED EFFECT | BAYER IP GMBH (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| EP-2536686-A1 | CYCLIC KETO-ENOLS FOR THERAPY | Bayer Intellectual Property GmbH (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-8247351-B2 | Insecticidal compositions having improved effect | BAYER CROPSCIENCE AG (DE) | 2012-08-21 | — | — | US | disclosed |
| US-8247351-B2 | Insecticidal compositions having improved effect | BAYER CROPSCIENCE AG (DE) | 2012-08-21 | — | — | US | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-2011098433-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | WO | disclosed |
| US-7928037-B2 | 3-biphenyl-substituted-3-substituted-4-ketolactam and ketolactone and their utilization as pesticide | BAYER CROPSCIENCE AG (DE) | 2011-04-19 | — | — | US | disclosed |
| US-7928037-B2 | 3-biphenyl-substituted-3-substituted-4-ketolactam and ketolactone and their utilization as pesticide | BAYER CROPSCIENCE AG (DE) | 2011-04-19 | — | — | US | disclosed |
| US-20100173778-A1 | 3-Biphenyl-substituted-3-substituted-4-ketolactam and ketolactone and their utilization as pesticide | FISCHER REINER | 2010-07-08 | — | — | US | disclosed |
| US-20100173778-A1 | 3-Biphenyl-substituted-3-substituted-4-ketolactam and ketolactone and their utilization as pesticide | FISCHER REINER | 2010-07-08 | — | — | US | disclosed |
| US-20090209513-A1 | Insecticidal Compositions Having Improved Effect | BAYER CROPSCIENCE AG (DE) | 2009-08-20 | — | — | US | disclosed |
| US-20090209513-A1 | Insecticidal Compositions Having Improved Effect | BAYER CROPSCIENCE AG (DE) | 2009-08-20 | — | — | US | disclosed |
| US-7307044-B2 | 3-biphenyl-substituted-3-substituted-4-ketolactam and ketolactone and their utilization as pesticide | BAYER CROPSCIENCE AG (DE) | 2007-12-11 | — | — | US | disclosed |
| US-7307044-B2 | 3-biphenyl-substituted-3-substituted-4-ketolactam and ketolactone and their utilization as pesticide | BAYER CROPSCIENCE AG (DE) | 2007-12-11 | — | — | US | disclosed |
| WO-2007068428-A2 | INSECTICIDAL COMPOSITIONS CONTAINING PHENYL-SUBSTITUTED CYCLIC KETOENOLS | BAYER CROPSCIENCE AG (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | AKR1B1, AKR1C3, AKR1A1 | ACACB 310/4885ACACA 541/4885PGR 305/4885 |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | CYP46A1, LIPC, CYP27A1 | ACACB 85/4885ACACA 90/4885PGR 1372/4885 |
| US-20090209513-A1 | Insecticidal Compositions Having Improved Effect | PTEN, PIK3CG, PIK3CD | ACACB 632/4885ACACA 382/4885PGR 2614/4885 |
| US-20100173778-A1 | 3-Biphenyl-substituted-3-substituted-4-ketolactam and ketolactone and their utilization as pesticide | CYP2B6, CYP2A6, CYP1B1 | ACACB 627/4885ACACA 943/4885PGR 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.